ELVN fund manager activity
Enliven Therapeutics, Inc · Nasdaq. Reported by 2 tracked fund managers in their 13F filings, Q2 2025 to Q2 2026.
Q3 2025
| Manager | Activity | Shares | Value | % of portfolio | Filed |
|---|---|---|---|---|---|
| Stanley Druckenmiller - Duquesne Family Office | Added | 947,405 | $19,393,000 | 0.49% | Nov 14, 2025 |
Q2 2025
| Manager | Activity | Shares | Value | % of portfolio | Filed |
|---|---|---|---|---|---|
| Stanley Druckenmiller - Duquesne Family Office | New | 463,000 | $9,288,000 | 0.24% | Aug 15, 2025 |